Case studies of fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 2, 2005, Pages

  Abram, Paul ^a   Maass, Nicolai ^b   Rea, Daniel ^c   Simon, Sergio D ^d   Steger, Guenther G ^e  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

^c QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

'Faslodex'; Advanced breast cancer; Endocrine therapy; Fulvestrant; Human epidermal growth factor receptor 2; Visceral metastases

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; RECEPTOR BLOCKING AGENT; TAMOXIFEN; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; ASCITES; AXILLARY LYMPH NODE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CASE STUDY; CLINICAL TRIAL; COLON CANCER; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG USE; EXPERIENCE; FEMALE; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; INVASIVE CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOMA; MASTECTOMY; PAGET NIPPLE DISEASE; PLEURA METASTASIS; POSTMENOPAUSE; PUBLICATION; RECURRENT CANCER; VISCERAL METASTASIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PALLIATIVE CARE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 27144524897     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.08.008     Document Type: Article

References (23)

1. C.T. Chung R.W. Carlson Goals and objectives in the management of metastatic breast cancer Oncologist 8 2003 514-520
2. H.J. Harmsen Jr. A.J. Porsius Endocrine therapy of breast cancer Eur J Cancer Clin Oncol 24 1988 1099-1116
3. J.F. Robertson A.R. Dixon R.I. Nicholson I.O. Ellis C.W. Elston R.W. Blamey Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy Breast Cancer Res Treat 22 1992 221-227
4. G. Curigliano R. Rigo M. Colleoni et al. Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features Clin Breast Cancer 5 2004 125-130
5. S. Menard P. Casalini M. Campiglio S.M. Pupa E. Tagliabue Role of HER2/ neu in tumor progression and therapy Cell Mol Life Sci 61 2004 2965-2978
6. J.F.R. Robertson Incidence of polypharmacy in patients with breast cancer The Breast 14 2005 S39
7. Robertson JFR. Incidence of polypharmacy in patients with breast cancer. In: Poster presentation at the Ninth International Conference on Primary Therapy of Breast Cancer, 26-29 January 2005, St. Gallen, Switzerland (poster 83).
8. L. Fallowfield L. Atkins R. Morris et al. Routes of administration in breast cancer: Preliminary findings from a patient survey The Breast 14 Suppl. 1 2005 S51 (abstr P126)
9. Fallowfield L, Atkins L, Morris R, et al. Routes of administration in breast cancer: Preliminary findings from a patient survey. In: Poster presentation at the Ninth International Conference on Primary Therapy of Breast Cancer, 26-29 January 2005, St Gallen, Switzerland (poster 126).
10. A. Howell J.F.R. Robertson A.J. Quaresma et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396-3403
11. C.K. Osborne J. Pippen S.E. Jones et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial J Clin Oncol 20 2002 3386-3395
12. J.F. Robertson C.K. Osborne A. Howell et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
13. L. Mauriac J.E. Pippen A.J. Quaresma S.Z. Gertler C.K. Osborne Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials Eur J Cancer 39 2003 1228-1233
14. J.N. Ingle K.M. Rowland V.J. Suman et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group Breast Cancer Res Treat 88 Suppl. 1 2004 S38 (abstr 409)
15. L. Perey R. Paridaens F. Nolé et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial Breast Cancer Res Treat 88 Suppl. 1 2004 S236 (abstr 6048)
16. G. Steger R. Bartsch C. Wenzel et al. Fulvestrant (Faslodex®) in metastatic breast cancer Breast Cancer Res Treat 82 Suppl. 1 2003 S104 (abstr 437)
17. S. Franco A. Perez E. Tan-Chiu C. Frankel C.L. Vogel Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience Breast Cancer Res Treat 88 2004 103-108
18. L. Petruzelka M. Zimovjanova B. Konopasek P. Mares Z. Dlouha Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - updated results from an expanded access programme Ann Oncol 15 Suppl. 3 2004 iii36 (abstr 136P)
19. S.E. Jones J. Pippen A. Webster A retrospective analysis of the proportion of patients responding for >1, 1.5 and 2 years in two phase III studies of fulvestrant versus anastrozole Breast Cancer Res Treat 88 Suppl. 1 2004 S236 (abstr 6047)
20. S.J. Houston T.A. Plunkett D.M. Barnes P. Smith R.D. Rubens D.W. Miles Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer Br J Cancer 79 1999 1220-1226
21. M. Dowsett C. Harper-Wynne I. Boeddinghaus et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res 61 2001 8452-8458
22. S. Menard S.M. Pupa M. Campiglio E. Tagliabue Biologic and therapeutic role of HER2 in cancer Oncogene 22 2003 6570-6578
23. A. Howell The future of fulvestrant ('Faslodex') Cancer Treatment Rev 31 Suppl. 2 2005 S26-S33